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Systematic review
Meta-analysis of risk of developing malignancy in congenital
choledochal malformation
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Groningen and University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands (e-mail: anneketenhove@me.com)
Background: Choledochal malformations comprise various congenital cystic dilatations of the extrahep-
atic and/or intrahepatic biliary tree. Choledochal malformation is generally considered a premalignant
condition, but reliable data on the risk of malignancy and optimal surgical treatment are lacking. The
objective of this systematic review was to assess the prevalence of malignancy in patients with chole-
dochal malformation and to differentiate between subtypes. In addition, the risk of malignancy following
cystic drainage versus complete cyst excision was assessed.
Methods: A systematic review of PubMed and Embase databases was performed in accordance with the
PRISMA statement. A meta-analysis of the risk of malignancy following cystic drainage versus complete
cyst excision was undertaken in line with MOOSE guidelines. Prevalence of malignancy was defined as
the rate of biliary cancer before resection, and malignant transformation as new-onset biliary cancer after
surgery.
Results: Eighteen observational studies were included, reporting a total of 2904 patients with a median
age of 36 years. Of these, 312 in total developed amalignancy (10⋅7 per cent); the prevalence ofmalignancy
was 7⋅3 per cent and the rate of malignant transformation was 3⋅4 per cent. Patients with types I and IV
choledochal malformation had an increased risk of malignancy (P = 0⋅016). Patients who underwent cystic
drainage had an increased risk of developing biliary malignancy compared with those who had complete
cyst excision, with an odds ratio of 3⋅97 (95 per cent c.i. 2⋅40 to 6⋅55).
Conclusion: The risk of developing malignancy among patients with choledochal malformation was
almost 11 per cent. The malignancy risk following cystic drainage surgery was four times higher than that
after complete cyst excision. Complete surgical resection is recommended in patients with choledochal
malformation.
Paper accepted 22 November 2017
Published online 26 February 2018 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.10798
Introduction
Choledochal cysts are congenital cystic dilatations of the
extrahepatic and/or intrahepatic biliary tree.Owing to vari-
ation in involvement of the biliary tree among subtypes of
choledochal cysts and new insights into epithelial mark-
ers, the more recent term for this condition is choledochal
malformation1,2. Choledochal malformations occur three
to four times more often in women. Choledochal mal-
formations are fairly common in the Asian population3
and rarer in Western countries. Choledochal malforma-
tion is considered a premalignant condition, but to date
its carcinogenic mechanisms have not been elucidated4.
This risk of cancer provides the basis for the current
treatment concept: surgical resection of the entire affected
biliary tract with subsequent construction of a biliodiges-
tive anastomosis. The bilioenteric anastomosis can be a
hepaticojejunostomy or hepaticoduodenostomy.Hepatico-
duodenostomy is associated with more complications, such
as cholangitis and bile reflux, and also with development of
malignancy5. Therefore, complete cyst excision followed
by a Roux-en-Y hepaticojejunostomy is the standard pro-
cedure nowadays. In asymptomatic patients, this treatment
might be considered as prophylactic surgery. Previously,
drainage procedures such as cystoduodenostomy were also
performed, but such procedures seem to have a much
higher risk of malignancy because abnormal biliary epithe-
lium remains in situ6,7.
© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS 2018; 105: 482–490
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Fig. 1 Todani classification of choledochal malformations5
Malignancies develop in 2⋅5–26 per cent of patients with
choledochal malformation4. Choledochal malformations
are classified according to Todani and colleagues (Fig. 1)5.
Several authors8–11 consider the development of malig-
nancy in choledochal malformations to be related to the
aetiology of the different types of malformation. It could
be speculated that prolonged reflux of pancreatic secre-
tions into the biliary tract occurs in Todani types I and IV,
which frequently present with abnormal pancreaticobiliary
duct junctions12. Prolonged reflux might lead to malignant
degeneration of the biliary epithelium8,13. The situation is
supposedly different in types II and III choledochal malfor-
mations, which might be true congenital malformations in
which reflux is absent14.
Precise estimates of the risk of carcinogenesis in
choledochal malformation are lacking. The aim of this sys-
tematic review was to assess the prevalence of malignancy
in both paediatric and adult patients with choledochal
malformation, and to determine the possible differences
between Todani types I and IV versus types II and III. The
secondary aim was to investigate the risk of malignant
transformation in patients with choledochal malforma-
tion who either did or did not undergo surgery, and
to investigate the prevalence of malignancy by decade
of age.
Methods
This systematic review was conducted in accordance with
the PRISMA statement15. Two reviewers independently
selected studies, extracted data and appraised the stud-
ies critically. Any differences of opinion between review-
ers were resolved by discussion. If they failed to reach
agreement, a third reviewer was consulted to achieve con-
sensus. This review was registered in PROSPERO, the
international database of prospectively registered system-
atic reviews (CRD42016048392)16.
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 482–490
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Literature search strategy
A systematic search of the PubMed and Embase databases
was performed for articles relevant to the prevalence of
malignancies and/or malignant transformations in patients
with choledochal malformation, published between
1 January 1995 and 1 June 2016. The electronic searches
were supplemented by manual reference checks of papers
in recent reviews. The Medical Subject Headings (MeSH)
terms ‘choledochal malformation’, ‘bile duct cyst’, ‘malig-
nant’ and ‘carcinoma’ were used for both databases. For
searching in Embase, the keyword ‘common bile duct cyst’
was added.
Definitions
Prevalence of malignancy was defined as the presence of
a gallbladder carcinoma and/or cholangiocarcinoma at the
time of diagnosis or an incidental finding during surgery
without previous intervention. Prevalence of malignancy is
the primary risk of malignancy in choledochal malforma-
tion and can be considered as risk of malignancy according
to the natural history of disease. Malignant transformation
was defined as the development of a cholangiocarcinoma
following a surgical drainage procedure or formal excision
of the choledochal malformation.
Literature screening
According to the PRISMA guidelines, the studies were
selected in three phases (Fig. 2). During the identifi-
cation phase, duplicates from different databases were
removed. During the screening phase, abstracts of all stud-
ies accepted during the identification phase were reviewed.
Reasons for exclusion were language other than English,
reviews, case reports, studies with fewer than ten patients,
and studies with a subject that was not relevant. During the
eligibility phase, the methodological quality of the studies
was assessed using the Newcastle–Ottawa Scale (NOS) for
cohort studies17.
Data extraction and critical appraisal
Predesigned forms were used in triplicate to record the
data. Data included: study design, patient population,
choledochal malformation type, follow-up time, type of
surgery, and prevalence of malignancy and/or transforma-
tion. Multiple publications describing the same or overlap-
ping series of patients were identified, and the data included
only once to avoid double counting. The level of evidence
for each article was assessed using the Levels of Evidence
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Fig. 2 Flow chart showing selection of articles for review. NOS,
Newcastle–Ottawa Scale
Medicine18. Quality of the articles was assessed according
to the NOS for cohort studies. This scale scores selec-
tion, comparability and outcome, with a maximum score
of 9 points. Only studies that scored at least 5 points were
included in the review. Overall quality of the evidence
was judged by means of the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
approach19.
Statistical analysis
Categorical variables, reported as numbers with percent-
ages, were analysed using the χ2 test. Overall effects were
determined using the Z score. Statistical significance was
defined as P< 0⋅050 (2-sided). The χ2 statistic and the
inconsistency quantity I2 were used to determine hetero-
geneity. An I2 value of 50 per cent or more represented
substantial heterogeneity20. A meta-analysis, with develop-
ment of malignancy as outcome measure, was performed
using RevMan software (Review Manager version 5.0.21;
Nordic Cochrane Centre, Copenhagen, Denmark) and the
results were displayed in a forest plot. The meta-analysis
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 482–490
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Moslim et al.22 USA 1984–2014 5 67 2⋅1 (0⋅4–4⋅2)† 5 (7) 3 (60) 55 (47–74) 5 (7) – –
Xia et al.23 China 1994–2013 7 268 8⋅3 (1⋅5–18⋅8)† 55 (20⋅5) n.a. 54⋅3 (32–75) 15 (5⋅6) 40 (14⋅9) n.a.
Soares et al.24 USA 1972–2014 6 394 2⋅3 25 (6⋅3) n.a. 57 12 (3⋅0) 13 (3⋅3) n.a.
Machado et al.25 Oman 1998–2013 5 10 6⋅0 (0⋅3–12)† 0 (0) – – – – –
He et al.26 China 1968–2013 6 214 9⋅3 15 (7⋅0) 12 (80) 49 (28–75) 10 (4⋅7) 5 (2⋅3) 15 (6–37)
Katabi et al.27 USA 1990–2008 5 36 n.a. 5 (14) 4 (80) 52 (35–65) 5 (14) 0 (0) –
Mabrut et al.28 France 1978–2011 6 155 2⋅9 (0⋅3–25)† 8 (5⋅2) 4 (50) 66⋅5 (54–74) 8 (5⋅2) 0 (0) –
Ohashi et al.29 Japan 1971–2006 6 94 15⋅1 (0⋅6–40⋅3)† 4 (4) 3 (75) 44 (27–65) 0 (0) 4 (4) 19 (13–32)
Lee et al.30 South Korea 1990–2007 6 808 4⋅3 80 (9⋅9) n.a. 50 (21–82) 74 (9⋅2) 6 (0⋅7) 4 (1–20)
Takeshita et al.31 Japan 1968–2008 5 180 8⋅3 (0⋅1–28⋅8) 37 (20⋅6) n.a. n.a. 36 (20⋅0) 1 (0⋅6) 1
Cho et al.32 South Korea 1995–2009 5 204 5⋅6 (0⋅8–15)† 22 (10⋅8) 10 (45) 48 20 (9⋅0) 2 (1⋅0) 0⋅8 (0⋅5–1⋅1)
Huang et al.33 Taiwan 1981–2006 5 94 8⋅9 (2–26) 11 (12) 7 (64) 57 (32–82) 11 (12) 0 (0) –
Ono et al.34 Japan 1981–2008 6 56 17 (10–27) 2 (4) 2 (100) 19 (12–26) 1 (2) 1 (2) 26
Liu et al.35 China 1981–2006 6 153 10 (1–18) 16 (10⋅5) n.a. n.a. 0 (0) 16 (10⋅5) n.a.
Wiseman et al.36 Canada 1985–2002 6 51 5⋅1 (2–18) 4 (8) n.a. n.a. 2 (4) 2 (4) n.a.
Liu et al.37 China 1989–2000 6 30 5⋅5† 9 (30) n.a. 43 (29–64) 5 (17) 4 (13) n.a.
Lenriot et al.7 France 1980–1992 6 42 6⋅9 (0⋅4–16) 5 (12) 5 (100) 40 (29–51) 2 (5) 3 (7) 16 (18–27)
Ishibashi et al.38 Japan 1975–1996 6 48 n.a. 9 (19) 6 (67) 49 (28–66) 6 (13) 3 (6) 10 (1⋅3–27)
Overall 2904 312 (10⋅7) 212 (7⋅3) 100 (3⋅4)
Values in parentheses are percentages unless indicated otherwise; values are *mean (range) and †median (range). The quality of evidence in all studies was
level 4 on the Oxford Levels of Evidence scale. n.a., Not available.
was carried out in accordance with MOOSE guidelines21.
Only studies that provided information on the parame-
ters analysed were included. Statistical analysis was per-
formed using SPSS version 23.0 (IBM, Armonk,NewYork,
USA).
Results
Of 1363 records identified during the initial search, 18 fell
within the scope of this study7,22–38 (Fig. 2). All records
represented retrospective observational studies. The stud-
ies scored at least 5 of 9 on the NOS scale, and provided
evidence at level 4 on the Oxford Levels of Evidence scale
(Table 1).
Ethnicity, sex and type of choledochal
malformation
Characteristics of the 18 studies are summarized in
Table 1. Six23,29–32,37 studies described Asian populations,
one7 described a European population, one25 a Middle
Eastern population, one22 a population with Caucasian
patients, and four studies24,27,28,36 described populations
with both Asian and Caucasian patients. The remaining
five studies26,33–35,38 did not specifically describe the
study population, but were authored by Asian institu-
tions. The 18 studies reported on a total of 2904 patients,
1655 (57⋅0 per cent) of whom were of Asian descent and
669 (23⋅0 per cent) of non-Asian descent; descent was
unknown for 580 patients (20⋅0 per cent). The sex of 2636
patients was known; of these, 1925 (73⋅0 per cent) were
women.
The type of choledochal malformation was available for
2304 patients. The majority of patients (2049, 88⋅9 per
cent) had types I or IV malformations, 59 (2⋅6 per cent)
had types II or III and 196 (8⋅5 per cent) had Type V. Two
studies did not provide follow-up data27,38. Themedian age
at time of diagnosis was 36 (range 0⋅1–82) years.
Malignancy rate
Overall, 312 of the 2904 patients (10⋅7 per cent) devel-
oped a malignancy. This was subdivided into tumours
present during primary surgery, which was the case in
212 patients (7⋅3 per cent), and tumours that devel-
oped during follow-up, which affected 100 patients (3⋅4
per cent). Of these 100 patients, 42 (42⋅0 per cent)
were treated with some kind of drainage procedure,
36 (36⋅0 per cent) underwent complete cyst excision fol-
lowed by a Roux-en-Y hepaticojejunostomy, and in 22
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 482–490
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Fig. 3 Age at development of malignancy in relation to
prevalence of malignancy, and development of malignant
transformation after drainage and after hepaticojejunostomy.
Data from six studies7,22,26,32,34,38 comprising 58 patients
patients (22⋅0 per cent) the treatment was unknown. Infor-
mation about survival of patients with malignancy was
provided by ten studies7,22,26–29,32–34,38. Included studies
reported mortality rates of between 45 and 100 per cent
(Table 1).
Age at development of malignancy
Six studies7,22,26,32,34,38 (comprising 58 patients) provided
detailed information on age at which malignancies devel-
oped. Of these 58 patients, 41 were aged less than 60
years. There was one 12-year-old child with a malignancy.
The number of patients per age decade is shown in Fig. 3.
Of the other 11 studies that reported the development
of malignancies, only eight reported median age. The
median age was less than 60 years in all but one of these
studies23,27–30,33,37. The median age of patients with
choledochal malformation at presentation of malignancy
for each study is illustrated in Fig. 4. The median age at
which malignancy developed was 49⋅5 years (14 studies);
three studies31,35,36 lacked this information. One study25
reported no development of malignancy. The malignancy
rates and median age at detection of malignancy are shown
in Table 1.
Type of choledochal malformation
and development of malignancy
Thirteen studies7,22–26,28–31,34,36,38 (2304 patients) pro-
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Fig. 4 Median age of patients with choledochal malformation at
presentation of malignancy in each study. The size of each blue
circle indicates the study sample size, and that of each red circle
the incidence of choledochal malformation, relative to that in the
other studies
type of choledochal malformation (Table 2). Malignancies
were found during initial surgery in 167 patients. Of these,
153 had types I or IV choledochal malformation (91⋅6 per
cent). Malignant transformation was found in 78 patients,
almost exclusively among those with types I or IV malfor-
mations (77 of 78, 99 per cent) (P= 0⋅016). One patient
with a type V malformation had malignant transforma-
tion. Types II and III were not associated with malignant
transformation.
Type of resection and development of malignancy
A meta-analysis including nine studies7,23,26,30,32,35–38
(1577 patients) was undertaken to investigate the influ-
ence of previous drainage procedures versus resection
with hepaticojejunostomy as a risk factor for developing
malignancy (Fig. 5). The remaining nine studies were not
included in this analysis as they did not report malignant
transformation22,25,27,28,33 or provided no information
about the type of treatment24,29,31,34. Of the 1574 patients,
1270 were treated with hepaticojejunostomy and 304 with
some type of drainage procedure. Malignant transforma-
tion was found in 24 of 1270 patients who underwent
hepaticojejunostomy and 56 of 304 treated with drainage
(P< 0⋅001). Patients who underwent cystic drainage had
an increased risk of developing biliary malignancy com-
pared with those who underwent complete cyst excision,
with an odds ratio of 3⋅97 (95 per cent c.i. 2⋅40 to 6⋅55).
Eight studies7,26,29–32,34,38 provided information about the
time interval between surgery and detection of malignancy
(Table 1).
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 482–490
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after complete cyst excision
I/IV 2049 (88⋅9) 153 (7⋅5) 1896 42 (2⋅2) 35 (1⋅8)
II/III 59 (2⋅6) 3 (5) 56 0 (0) 0 (0)
V 196 (8⋅5) 11 (5⋅6) 185 0 (0) 1 (0⋅5)
Overall 2304 167 2137 42 36
Values in parentheses are percentages. Types of choledochal malformation were defined in accordance with the Todani classification5. Thirteen

















































Favours drainage Favours cyst excision
1 10 100
Total
Heterogeneity: χ2=21·66, 8 d.f., P=0·006; I2=63%
Test for overall effect: Z=5·38, P<0·001
Reference
Development of malignancy
Drainage Cyst excision Weight (%) Odds ratio Odds ratio
Fig. 5 Forest plot comparing development of malignancy in patients treated with drainage procedures and compared with those who
underwent complete cyst excision followed by a Roux-en-Y hepaticojejunostomy. A Mantel–Haenszel fixed-effect model was used for
meta-analysis. Odds ratios are shown with 95 per cent confidence intervals
Discussion
Choledochal malformation is considered a premalignant
condition, even though scientific evidence in support of this
is relatively scarce. The results of this systematic review and
meta-analysis showed that malignancies may develop in up
to 11 per cent of patients with choledochal malformation.
The risk of developing malignancy was four times greater
among patients treated with drainage procedures rather
than complete cyst excisions, especially those with types I
or IV malformations.
Eighteen studies7,22–38 that reported on the devel-
opment of malignancies in patients with choledochal
malformation were identified in this review. The preva-
lence of malignancy was 7⋅3 per cent among patients
with choledochal malformation and the rate of malignant
transformation was 3⋅4 per cent. This finding implies
that treating choledochal malformation may reduce the
risk of developing malignancy, and is consistent with the
commonly accepted theory that carcinogenesis might
be related to dysplasia and metaplasia of the epithelium
of the choledochal malformation6–8,13. Complete cyst
excision followed by construction of a bilioenteric anas-
tomosis is therefore believed to protect the patient from
developing malignancy39,40. This also holds true for the
other pathophysiological mechanisms that have been
proposed, such as genetic deletions and heredity; thus
surgical resection of the affected biliary tract remains
the mainstay of therapy. Nevertheless, a malignant trans-
formation rate of 3⋅4 per cent, mainly in patients who
underwent drainage procedures, is a relatively high pro-
portion. In the past, drainage procedures, whereby the
cyst remained intact and surgery was limited to cysten-
terostomy, were popular. Such operations are no longer
performed because of the assumed higher risk of develop-
ing malignancy6,7. These assumptions were corroborated
by the present finding that patients treated with drainage
procedures had nearly a fourfold higher risk of malignancy
compared with patients who underwent complete cyst
excision. This implies that patients who have undergone
drainage procedures are at increased risk of developing
malignancies throughout their lives. Even though the
overall postoperative complication rate of complete cyst
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 482–490
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excision followed by hepaticojejunostomy is between 15
and 20 per cent24,40, this outweighs the poor prognosis
if a malignancy develops, with a 5-year survival rate of
merely 5 per cent41. Therefore, it is recommended that
patients who have undergone drainage procedures in the
past be reoperated with complete cyst excision followed by
hepaticojejunostomy.
No differences in the prevalence of malignancy between
the different types of choledochal malformation were
found in the present study. Patients who had surgery for
choledochal malformation types I or IV had a significantly
increased risk of malignant transformation compared
with those with choledochal malformation types II or
III. This difference may be related to the aetiology of
the different types of choledochal malformation. It may
be speculated that Todani types I and IV malformations
are both associated with an abnormal pancreaticobiliary
duct junction and that the prolonged reflux of pancreatic
secretions into the biliary tract is not only responsible
for the dilatation of the biliary tract, but might also lead
to malignant degeneration42. However, based on the
present data it cannot be confirmed or refuted that the
presence of an abnormal pancreaticobiliary duct junction
is a precondition for the development of carcinoma. A
hyperplasia–dysplasia–carcinoma sequence, as observed
in the colon or oesophagus, was suggested based on patho-
logical findings42. According to the Todani classification,
type I choledochal malformation has no intrahepatic
involvement and it is therefore illogical that malignant
transformation could occur in the intrahepatic biliary tree
after complete cyst excision. Malignant transformation in
the intrahepatic biliary tree has, however, been reported in
patients with type I choledochal malformation7,24,26,29,30,38.
This may be explained by the theory that types I and IV
malformations are essentially the same lesions43.Malignant
transformation in patients with types I and IV choledochal
malformation could be associated with chronic inflamma-
tion of the biliary tree owing to (low-grade) cholangitis29.
As types II and III malformations are not associated with
an abnormal pancreaticobiliary duct junction, they might
have a different aetiology and a different malignant degen-
eration process, if such a process exists. Type V might be a
completely different entity involving the intrahepatic ducts
alone and often requiring a liver transplantation. Because
of the higher risk of malignant transformation in patients
with types I and/or IV choledochal transformations, it is
of utmost importance to monitor these patients carefully.
Previous studies have invariably highlighted age as
a possible risk factor. It is commonly accepted that
the risk of malignancy increases with increasing age at
presentation30,44. Nicholl and colleagues44 reported a
malignancy risk of zero among patients aged less than 30
years, compared with 50 per cent in patients older than
51 years. The present review found a similar trend, with
a peak between 61 and 70 years. Even though the risk of
developing malignancy increases with age, the results of
this systematic review showed a strikingly younger age at
which malignancy developed in patients with choledochal
malformation (median 49⋅5 years) in comparison with
the general cholangiocarcinoma population (median 65
years)41. This is 20 years younger than in the general
population41. Therefore, when a choledochal malforma-
tion is confirmed, a complete cyst excision is warranted,
even in an asymptomatic elderly patient.
The incidence of choledochal malformation is higher
among patients of Asian descent, so most literature on
malignant transformation refers to the Asian population.
The limited data found in this review suggest a similar risk
of developingmalignancy amongAsian andCaucasian pop-
ulations. Although the incidence of choledochal malforma-
tion is higher in the Asian population, it seems that once a
choledochal malformation is present the risk of developing
malignancy is independent of ethnicity. Regarding patients
without a choledochal malformation, the Asian population
also has an increased baseline risk of developing cholan-
giocarcinoma compared with the Caucasian population41.
This predisposition provides a clear argument in favour of
there being a genetic background for the development of
adenocarcinoma in abnormal epithelium. Caution should
be exercised when interpreting the literature of mostly
retrospective series, because the Asian andCaucasian popu-
lations are not comparable. Further research on malignant
transformations in the Caucasian population is required.
Caucasians represented 20 per cent of the patients in the
present review; this proportion is too small for conclusions
to be drawn about this population.
This systematic review and meta-analysis is based on the
results of 18 retrospective cohort studies, with wide vari-
ation in sample size (ranging from 10 to 808 patients),
moderate study quality and likelihood of selection bias45.
The overall quality of evidence according to the GRADE
criteria19 had to be downgraded owing to sparse and impre-
cise data, and uncertainty about the baseline risk for the
population of interest. However, this systematic review
used current standards, including PRISMA, MOOSE and
GRADE guidelines. By applying strict study quality and
methodological assessment using theNOS for cohort stud-
ies, the best available evidence was extracted, which could
be helpful in addressing this complex clinical problem.
However, collaborative international initiatives such as the
Biliary Atresia and Related Diseases database46 are instru-
mental in obtaining a more precise risk estimate for the
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 482–490
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development of malignancy in patients with choledochal
malformation.
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